The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Targeted drug delivery to tumors: Myths, reality and possibility
Open accessAbstract
The ultimate goal of drug delivery research is to help patients by developing clinically useful formulations. During the last several decades controlled drug delivery technology has advanced significantly, leading to the development of various clinical formulations improving patient compliance and convenience [1]. Current technologies allow delivery of drugs at desired release kinetics for extended periods of time ranging from days to years. Oral and transdermal drug delivery systems routinely deliver drugs for 24 h, substantially improving drug efficacy and minimizing side effects. Implantable systems can locally deliver drugs for months, even years. While significant advances have been made, there are still areas where substantial improvements need to be made to reach the next level of clinical relevance. One such area is targeted drug delivery to solid tumors. The clinically significant impact of targeted drug delivery lies in the ability to specifically target a drug or drug carrier to minimize drug-originated systemic toxic effects. Successful translation (from bench to bedside) of potential cancer and gene therapies, particularly small interfering RNA (siRNA) delivery, will largely depend on targeted drug delivery strategies. Overcoming the many challenges of identifying a successful targeted drug delivery strategy requires an understanding of events involving transport of drug or drug carrier to a target site after intravenous (i.v.) administration as well as issues relevant for specific target diseases and the body’s response toward a drug delivery system. The current lack of clear recognition of problems facing the drug delivery field can be anticipated to result in only marginal advances in targeted drug delivery technologies in the coming years. The current unmet needs and challenges in this area were summarized by Professor Alexander T. Florence who is one of the few who raised awareness on the exaggerated claims of the nanoparticle-based drug targeting [2,3]. They need to be better appreciated and understood for achieving greater success in drug targeting to tumors. Thus, it would be profitable to address a variety of issues and factors that could affect the development of improved targeted drug delivery systems. Many terms have been used to describe nano-sized drug delivery systems, and here the term “nanoparticle” is used to represent a spectrum of systems, including nanocarrier, nanovehicle, nanosystem, nanostructure, and other terms used in the literature.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
Textbook of Medical Physiology
(1966) · Annals of Internal Medicine · doi:10.7326/0003-4819-64-6-1363_2 · Cited by 9,749
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
OWENSIII, D., & PEPPAS, N. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.10.010 · Cited by 3,637
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,515
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
Gupta, P. B., Onder, T. T., Jiang, G., Tao, K., Kuperwasser, C., Weinberg, R. A., & Lander, E. S. (2009) · Cell · doi:10.1016/j.cell.2009.06.034 · Cited by 2,389
Cited by
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Wiklander, O. P. B., Nordin, J. Z., O'Loughlin, A., Gustafsson, Y., Corso, G., Mäger, I., Vader, P., Lee, Y., Sork, H., Seow, Y., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.26316 · Cited by 1,730
Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery
Torchilin, V. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4333 · Cited by 1,663
Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors
Din, F. U., Aman, W., Ullah, I., Qureshi, O. S., Mustapha, O., Shafique, S., & Zeb, A. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s146315 · Cited by 1,577
Nanoparticle uptake: The phagocyte problem
Gustafson, H. H., Holt-Casper, D., Grainger, D. W., & Ghandehari, H. (2015) · Nano Today · doi:10.1016/j.nantod.2015.06.006 · Cited by 1,411
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review
Hossen, S., Hossain, M. K., Basher, M. K., Mia, M. N. H., Rahman, M. T., & Uddin, M. J. (2019) · Journal of Advanced Research · doi:10.1016/j.jare.2018.06.005 · Cited by 998
“Active targeting uses overexpressed cell surface receptors of cancer cells to target cancer cells directly like a guided missile [14].”
BackgroundDai, Y., Xu, C., Sun, X., & Chen, X. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00592f · Cited by 931
Controlled drug delivery systems: Past forward and future back
Park, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.054 · Cited by 720
Self-citationOvercoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
The journey of a drug-carrier in the body: An anatomo-physiological perspective
Bertrand, N., & Leroux, J.-C. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.098 · Cited by 707
Quantifying the Ligand-Coated Nanoparticle Delivery to Cancer Cells in Solid Tumors
Dai, Q., Wilhelm, S., Ding, D., Syed, A. M., Sindhwani, S., Zhang, Y., Chen, Y. Y., MacMillan, P., & Chan, W. C. W. (2018) · ACS Nano · doi:10.1021/acsnano.8b03900 · Cited by 658
Magnetic nanocarriers: Evolution of spinel ferrites for medical applications
Amiri, M., Salavati-Niasari, M., & Akbari, A. (2019) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2019.01.003 · Cited by 651
Feng, T., Ai, X., An, G., Yang, P., & Zhao, Y. (2016) · ACS Nano · doi:10.1021/acsnano.6b00043 · Cited by 650
Quantum dots in biomedical applications
Wagner, A. M., Knipe, J. M., Orive, G., & Peppas, N. A. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.05.022 · Cited by 632
Survey of Clinical Translation of Cancer Nanomedicines—Lessons Learned from Successes and Failures
He, H., Liu, L., Morin, E. E., Liu, M., & Schwendeman, A. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00228 · Cited by 588
Selenium-Containing Polymers: Promising Biomaterials for Controlled Release and Enzyme Mimics
Xu, H., Cao, W., & Zhang, X. (2013) · Accounts of Chemical Research · doi:10.1021/ar4000339 · Cited by 586
Polymeric Conjugates for Drug Delivery
Larson, N., & Ghandehari, H. (2012) · Chemistry of Materials · doi:10.1021/cm2031569 · Cited by 580
Li, X., Corbett, A. L., Taatizadeh, E., Tasnim, N., Little, J. P., Garnis, C., Daugaard, M., Guns, E., Hoorfar, M., & Li, I. T. S. (2019) · APL Bioengineering · doi:10.1063/1.5087122 · Cited by 564
Facing the Truth about Nanotechnology in Drug Delivery
Park, K. (2013) · ACS Nano · doi:10.1021/nn404501g · Cited by 544
Self-citationLigand-targeted liposome design: challenges and fundamental considerations
Noble, G. T., Stefanick, J. F., Ashley, J. D., Kiziltepe, T., & Bilgicer, B. (2014) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.09.007 · Cited by 542
Network Pharmacology Approach for Medicinal Plants: Review and Assessment
Noor, F., Tahir ul Qamar, M., Ashfaq, U. A., Albutti, A., Alwashmi, A. S. S., & Aljasir, M. A. (2022) · Pharmaceuticals · doi:10.3390/ph15050572 · Cited by 540
Improving drug delivery to solid tumors: Priming the tumor microenvironment
Khawar, I. A., Kim, J. H., & Kuh, H.-J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.018 · Cited by 533
Zhang, Y., Wang, Z., & Gemeinhart, R. A. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.09.015 · Cited by 535
Safety of Nanoparticles in Medicine
Wolfram, J., Zhu, M., Yang, Y., Shen, J., Gentile, E., Paolino, D., Fresta, M., Nie, G., Chen, C., Shen, H., et al. (2015) · Current Drug Targets · doi:10.2174/1389450115666140804124808 · Cited by 532
Immune Cell Membrane‐Coated Biomimetic Nanoparticles for Targeted Cancer Therapy
Oroojalian, F., Beygi, M., Baradaran, B., Mokhtarzadeh, A., & Shahbazi, M. (2021) · Small · doi:10.1002/smll.202006484 · Cited by 528
Nanoparticles and targeted drug delivery in cancer therapy
Bahrami, B., Hojjat-Farsangi, M., Mohammadi, H., Anvari, E., Ghalamfarsa, G., Yousefi, M., & Jadidi-Niaragh, F. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.07.015 · Cited by 510
Polymeric Nanostructures for Imaging and Therapy
Elsabahy, M., Heo, G. S., Lim, S.-M., Sun, G., & Wooley, K. L. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00135 · Cited by 508
Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications
Spicer, C. D., Jumeaux, C., Gupta, B., & Stevens, M. M. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00877e · Cited by 497
Integrating Artificial Intelligence and Nanotechnology for Precision Cancer Medicine
Adir, O., Poley, M., Chen, G., Froim, S., Krinsky, N., Shklover, J., Shainsky‐Roitman, J., Lammers, T., & Schroeder, A. (2020) · Advanced Materials · doi:10.1002/adma.201901989 · Cited by 496
Biodistribution of extracellular vesicles following administration into animals: A systematic review
Kang, M., Jordan, V., Blenkiron, C., & Chamley, L. W. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12085 · Cited by 485
Evolution of drug delivery systems: From 1950 to 2020 and beyond
Park, H., Otte, A., & Park, K. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.12.030 · Cited by 475
Self-citationCancer Stem Cells and Drug Resistance: The Potential of Nanomedicine
Vinogradov, S., & Wei, X. (2012) · Nanomedicine · doi:10.2217/nnm.12.22 · Cited by 474
Yang, Q., Guo, N., Zhou, Y., Chen, J., Wei, Q., & Han, M. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.04.004 · Cited by 471
Nanoparticle-Based Immunotherapy for Cancer
Shao, K., Singha, S., Clemente-Casares, X., Tsai, S., Yang, Y., & Santamaria, P. (2015) · ACS Nano · doi:10.1021/nn5062029 · Cited by 470
Nanoparticle-assisted ultrasound: A special focus on sonodynamic therapy against cancer
Canavese, G., Ancona, A., Racca, L., Canta, M., Dumontel, B., Barbaresco, F., Limongi, T., & Cauda, V. (2018) · Chemical Engineering Journal · doi:10.1016/j.cej.2018.01.060 · Cited by 457
Laurent, S., Saei, A. A., Behzadi, S., Panahifar, A., & Mahmoudi, M. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.924501 · Cited by 445
Micro‐/Nanorobots at Work in Active Drug Delivery
Luo, M., Feng, Y., Wang, T., & Guan, J. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201706100 · Cited by 440
Liang, Y., Zhao, X., Ma, P. X., Guo, B., Du, Y., & Han, X. (2019) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2018.10.056 · Cited by 433
Recent progress in development of siRNA delivery vehicles for cancer therapy
Kim, H. J., Kim, A., Miyata, K., & Kataoka, K. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.011 · Cited by 424
Li, S., Su, W., Wu, H., Yuan, T., Yuan, C., Liu, J., Deng, G., Gao, X., Chen, Z., Bao, Y., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0540-y · Cited by 424
Wu, W., Jiang, C. Z., & Roy, V. A. L. (2016) · Nanoscale · doi:10.1039/c6nr07542h · Cited by 417
Poly(2-oxazoline)s based biomaterials: a comprehensive and critical update
Lorson, T., Lübtow, M. M., Wegener, E., Haider, M. S., Borova, S., Nahm, D., Jordan, R., Sokolski-Papkov, M., Kabanov, A. V., & Luxenhofer, R. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.05.022 · Cited by 391
Analysis on the current status of targeted drug delivery to tumors
Kwon, I. K., Lee, S. C., Han, B., & Park, K. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.07.010 · Cited by 404
Self-citationLigand-targeted particulate nanomedicines undergoing clinical evaluation: Current status
van der Meel, R., Vehmeijer, L. J. C., Kok, R. J., Storm, G., & van Gaal, E. V. B. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.012 · Cited by 398
Tumor Redox Heterogeneity‐Responsive Prodrug Nanocapsules for Cancer Chemotherapy
Wang, J., Sun, X., Mao, W., Sun, W., Tang, J., Sui, M., Shen, Y., & Gu, Z. (2013) · Advanced Materials · doi:10.1002/adma.201300929 · Cited by 395
Lee, H., Shields, A. F., Siegel, B. A., Miller, K. D., Krop, I., Ma, C. X., LoRusso, P. M., Munster, P. N., Campbell, K., Gaddy, D. F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3193 · Cited by 393
Role of Nanoparticle Mechanical Properties in Cancer Drug Delivery
Hui, Y., Yi, X., Hou, F., Wibowo, D., Zhang, F., Zhao, D., Gao, H., & Zhao, C.-X. (2019) · ACS Nano · doi:10.1021/acsnano.9b03924 · Cited by 388
Neutrophil‐Based Drug Delivery Systems
Chu, D., Dong, X., Shi, X., Zhang, C., & Wang, Z. (2018) · Advanced Materials · doi:10.1002/adma.201706245 · Cited by 386
Bridging Bio–Nano Science and Cancer Nanomedicine
Björnmalm, M., Thurecht, K. J., Michael, M., Scott, A. M., & Caruso, F. (2017) · ACS Nano · doi:10.1021/acsnano.7b04855 · Cited by 382
Nanoparticle Characterization: State of the Art, Challenges, and Emerging Technologies
Cho, E. J., Holback, H., Liu, K. C., Abouelmagd, S. A., Park, J., & Yeo, Y. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300697h · Cited by 382
Tewabe, A., Abate, A., Tamrie, M., Seyfu, A., & Abdela Siraj, E. (2021) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s313968 · Cited by 375
Samrot, A. V., Sahithya, C. S., Selvarani A, J., Purayil, S. K., & Ponnaiah, P. (2021) · Current Research in Green and Sustainable Chemistry · doi:10.1016/j.crgsc.2020.100042 · Cited by 374
Designing Hydrogels for On-Demand Therapy
Oliva, N., Conde, J., Wang, K., & Artzi, N. (2017) · Accounts of Chemical Research · doi:10.1021/acs.accounts.6b00536 · Cited by 371
Gold nanoparticles: Emerging paradigm for targeted drug delivery system
Kumar, A., Zhang, X., & Liang, X.-J. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2012.10.002 · Cited by 371
Construction of iron oxide nanoparticle-based hybrid platforms for tumor imaging and therapy
Hu, Y., Mignani, S., Majoral, J.-P., Shen, M., & Shi, X. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00657h · Cited by 370
Photodynamic nanomedicine in the treatment of solid tumors: Perspectives and challenges
Master, A., Livingston, M., & Sen Gupta, A. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.02.020 · Cited by 367
Cheng, Y.-H., He, C., Riviere, J. E., Monteiro-Riviere, N. A., & Lin, Z. (2020) · ACS Nano · doi:10.1021/acsnano.9b08142 · Cited by 362
The advanced role of carbon quantum dots in nanomedical applications
Devi, P., Saini, S., & Kim, K.-H. (2019) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2019.02.059 · Cited by 349
Questioning the use of PEGylation for drug delivery
Verhoef, J. J. F., & Anchordoquy, T. J. (2013) · Drug Delivery and Translational Research · doi:10.1007/s13346-013-0176-5 · Cited by 342
Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions
Anchordoquy, T. J., Barenholz, Y., Boraschi, D., Chorny, M., Decuzzi, P., Dobrovolskaia, M. A., Farhangrazi, Z. S., Farrell, D., Gabizon, A., Ghandehari, H., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b08244 · Cited by 337
Brain-targeted drug delivery by manipulating protein corona functions
Zhang, Z., Guan, J., Jiang, Z., Yang, Y., Liu, J., Hua, W., Mao, Y., Li, C., Lu, W., Qian, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11593-z · Cited by 334
Towards clinically translatable in vivo nanodiagnostics
Park, S.-M., Aalipour, A., Vermesh, O., Yu, J. H., & Gambhir, S. S. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.14 · Cited by 327
Assessment of PEG on polymeric particles surface, a key step in drug carrier translation
Rabanel, J.-M., Hildgen, P., & Banquy, X. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.017 · Cited by 318
Nanoparticles' interactions with vasculature in diseases
Tee, J. K., Yip, L. X., Tan, E. S., Santitewagun, S., Prasath, A., Ke, P. C., Ho, H. K., & Leong, D. T. (2019) · Chemical Society Reviews · doi:10.1039/c9cs00309f · Cited by 314
Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?
Taurin, S., Nehoff, H., & Greish, K. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.07.013 · Cited by 309
Challenges in design and characterization of ligand-targeted drug delivery systems
Muro, S. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.052 · Cited by 307
Gao, H., Yang, Z., Zhang, S., Cao, S., Shen, S., Pang, Z., & Jiang, X. (2013) · Scientific Reports · doi:10.1038/srep02534 · Cited by 306
Nel, A., Ruoslahti, E., & Meng, H. (2017) · ACS Nano · doi:10.1021/acsnano.7b07214 · Cited by 302
Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics
Lorenzer, C., Dirin, M., Winkler, A.-M., Baumann, V., & Winkler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.003 · Cited by 284
Perspectives on the past, present, and future of cancer nanomedicine
Youn, Y. S., & Bae, Y. H. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.05.008 · Cited by 285
Self-citationNanoparticle–blood interactions: the implications on solid tumour targeting
Lazarovits, J., Chen, Y. Y., Sykes, E. A., & Chan, W. C. W. (2015) · Chemical Communications · doi:10.1039/c4cc07644c · Cited by 285
Setyawati, M. I., Tay, C. Y., Bay, B. H., & Leong, D. T. (2017) · ACS Nano · doi:10.1021/acsnano.7b01744 · Cited by 282
Tailoring nanoparticle designs to target cancer based on tumor pathophysiology
Sykes, E. A., Dai, Q., Sarsons, C. D., Chen, J., Rocheleau, J. V., Hwang, D. M., Zheng, G., Cramb, D. T., Rinker, K. D., & Chan, W. C. W. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521265113 · Cited by 281
Surface design of magnetic nanoparticles for stimuli-responsive cancer imaging and therapy
Kang, T., Li, F., Baik, S., Shao, W., Ling, D., & Hyeon, T. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.05.013 · Cited by 280
Zi, Y., Yang, K., He, J., Wu, Z., Liu, J., & Zhang, W. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114449 · Cited by 268
Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research
Egusquiaguirre, S. P., Igartua, M., Hernández, R. M., & Pedraz, J. L. (2012) · Clinical and Translational Oncology · doi:10.1007/s12094-012-0766-6 · Cited by 268
Yang, Z.-Z., Li, J.-Q., Wang, Z.-Z., Dong, D.-W., & Qi, X.-R. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.03.017 · Cited by 267
Ranjan, A., Jacobs, G. C., Woods, D. L., Negussie, A. H., Partanen, A., Yarmolenko, P. S., Gacchina, C. E., Sharma, K. V., Frenkel, V., Wood, B. J., et al. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.011 · Cited by 267
Use of magnetic fields and nanoparticles to trigger drug release and improve tumor targeting
Liu, J. F., Jang, B., Issadore, D., & Tsourkas, A. (2019) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1571 · Cited by 265
Design of Nanoparticle-Based Carriers for Targeted Drug Delivery
Yu, X., Trase, I., Ren, M., Duval, K., Guo, X., & Chen, Z. (2016) · Journal of Nanomaterials · doi:10.1155/2016/1087250 · Cited by 265
Unlocking the Power of Exosomes for Crossing Biological Barriers in Drug Delivery
Elliott, R. O., & He, M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010122 · Cited by 260
Strategic design of extracellular vesicle drug delivery systems
Armstrong, J. P. K., & Stevens, M. M. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.017 · Cited by 257
Xiao, H., Song, H., Yang, Q., Cai, H., Qi, R., Yan, L., Liu, S., Zheng, Y., Huang, Y., Liu, T., et al. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.05.049 · Cited by 200
Luo, Z., & Jiang, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.06.027 · Cited by 193
Engineered strategies to enhance tumor penetration of drug-loaded nanoparticles
Souri, M., Soltani, M., Moradi Kashkooli, F., & Kiani Shahvandi, M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.024 · Cited by 178
Shi, Y., Lammers, T., Storm, G., & Hennink, W. E. (2017) · Macromolecular Bioscience · doi:10.1002/mabi.201600160 · Cited by 174
Simulation of complex transport of nanoparticles around a tumor using tumor-microenvironment-on-chip
Kwak, B., Ozcelikkale, A., Shin, C. S., Park, K., & Han, B. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.08.027 · Cited by 165
Self-citationSenthil Kumar, C., Thangam, R., Mary, S. A., Kannan, P. R., Arun, G., & Madhan, B. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2019.115682 · Cited by 168
Nanocrystals: a perspective on translational research and clinical studies
Jarvis, M., Krishnan, V., & Mitragotri, S. (2019) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10122 · Cited by 162
Enhanced immunocompatibility of ligand-targeted liposomes by attenuating natural IgM absorption
Guan, J., Shen, Q., Zhang, Z., Jiang, Z., Yang, Y., Lou, M., Qian, J., Lu, W., & Zhan, C. (2018) · Nature Communications · doi:10.1038/s41467-018-05384-1 · Cited by 152
Advancing engineering design strategies for targeted cancer nanomedicine
Gomerdinger, V. F., Nabar, N., & Hammond, P. T. (2025) · Nature Reviews Cancer · doi:10.1038/s41568-025-00847-2 · Cited by 146
iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery
Kang, S., Lee, S., & Park, S. (2020) · Polymers · doi:10.3390/polym12091906 · Cited by 139
Nanoparticles: A New Approach to Upgrade Cancer Diagnosis and Treatment
Yu, Z., Gao, L., Chen, K., Zhang, W., Zhang, Q., Li, Q., & Hu, K. (2021) · Nanoscale Research Letters · doi:10.1186/s11671-021-03489-z · Cited by 138
Hou, L., Shan, X., Hao, L., Feng, Q., & Zhang, Z. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.03.005 · Cited by 128
Iron oxide-loaded nanotheranostics: major obstacles to in vivo studies and clinical translation
Schleich, N., Danhier, F., & Préat, V. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.11.024 · Cited by 124
Nakamura, T., Sato, Y., Yamada, Y., Abd Elwakil, M. M., Kimura, S., Younis, M. A., & Harashima, H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114417 · Cited by 121
Injectable, self-healing chimeric catechol-Fe(III) hydrogel for localized combination cancer therapy
Yavvari, P. S., Pal, S., Kumar, S., Kar, A., Awasthi, A. K., Naaz, A., Srivastava, A., & Bajaj, A. (2017) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.7b00741 · Cited by 85
Genetically Engineered Microorganisms and Their Impact on Human Health
Mahdizade Ari, M., Dadgar, L., Elahi, Z., Ghanavati, R., & Taheri, B. (2024) · International Journal of Clinical Practice · doi:10.1155/2024/6638269 · Cited by 67
Hyaluronan-conjugated liposomes encapsulating gemcitabine for breast cancer stem cells
Han, Shin, D. H., Kim, J. S., Weon, K. Y., Jang, C.-Y., & Kim, J.-S. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s95850 · Cited by 65
Metadata
- Authors
- Bae, Y. H., & Park, K.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2011-08
- Volume
- 153
- Issue
- 3
- Pages
- 198-205
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2070003597
- Cited by
- 1,935
- References
- 81
- FWCI
- 31.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.